Research Progress of IL-33/ST2 Signaling Pathway in Cardiovascular Disease
- 10.2991/meici-18.2018.98How to use a DOI?
- Interleukin-33; ST2; Atherosclerosis; Heart failure; Myocardial infarction
Soluble ST2 (sST2) is a protein of interleukin-1 (IL-1) receptor family, IL-33 is the special ligand of ST2, IL-33/ST2 signaling has a significantly effect in the inflammation and immunology diseases. It certified that ST2 can be secreted by the myocardial cells on the mechanical overload, and it can inhibit the anti-Hypertrophy and anti-fibrosis of IL-33, can induce the cardiac remodeling. New researches indict that ST2 effects on the process of atherosclerotic and is associated with incident hypertension. Higher sST2 is related to disease activity and adverse in coronary artery disease and heart failure. Aldosterone receptor antagonist plays an important role in the IL-33/ST2 pathway.
- © 2018, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Yang Wang AU - Bin Wang PY - 2018/12 DA - 2018/12 TI - Research Progress of IL-33/ST2 Signaling Pathway in Cardiovascular Disease BT - Proceedings of the 2018 8th International Conference on Management, Education and Information (MEICI 2018) PB - Atlantis Press SP - 495 EP - 499 SN - 1951-6851 UR - https://doi.org/10.2991/meici-18.2018.98 DO - 10.2991/meici-18.2018.98 ID - Wang2018/12 ER -